Filing Flows › Comparisons › MDGL vs SRPT
Madrigal Pharmaceuticals vs Sarepta Therapeutics: MDGL and SRPT compared
Madrigal Pharmaceuticals is the larger company: $431M of revenue in its latest quarter (Q3 2026) against $381M for Sarepta Therapeutics (Q3 2026). Madrigal Pharmaceuticals is growing faster (+50% against -4% a year earlier). Madrigal Pharmaceuticals is more profitable, with an operating margin of 13.0% against -2.4%.
Where the money goes: MDGL and SRPT
Madrigal Pharmaceuticals (MDGL) · Q3 2026
Madrigal Pharmaceuticals, Q3 2026: revenue $431M (+50% year over year), operating margin 13.0%, net earnings $55.4M, operating cash flow $121M. The chart follows the revenue to costs, profit and cash.
Sarepta Therapeutics (SRPT) · Q3 2026
Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart follows the revenue to costs, profit and cash.
| Madrigal Pharmaceuticals (MDGL) | Sarepta Therapeutics (SRPT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $431M | $381M |
| Revenue growth, Y/Y | +50% | -4% |
| Operating margin | 13.0% | -2.4% |
| Net earnings | $55.4M | −$28.5M |
| Net margin | 12.9% | -7.5% |
| Operating cash flow | $121M | $60.0M |
| Free cash flow | $117M | $57.0M |
| Market value | $12.1B | $1.9B |
| Analysts’ mean target | $688.94 | $21.68 |
Where the revenue comes from
Sarepta Therapeutics
- Pmo Products: $240M (63%)
- Elevidys: $83.5M (22%)
- Other revenues: $57.6M (15%)
Questions
Which is bigger, Madrigal Pharmaceuticals or Sarepta Therapeutics?
Madrigal Pharmaceuticals is the larger company: $431M of revenue in its latest quarter (Q3 2026) against $381M for Sarepta Therapeutics (Q3 2026).
Is Madrigal Pharmaceuticals or Sarepta Therapeutics growing faster?
Madrigal Pharmaceuticals is growing faster (+50% against -4% a year earlier).
Which is more profitable, Madrigal Pharmaceuticals or Sarepta Therapeutics?
Madrigal Pharmaceuticals is more profitable, with an operating margin of 13.0% against -2.4%.
More: Madrigal Pharmaceuticals earnings · how Madrigal Pharmaceuticals makes money · Sarepta Therapeutics earnings · how Sarepta Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.